The inhibition of VEFGA results in the reduction of MAPK phosphorylation and the downregulation of the anti-apoptotic marker BCL-2, indicating that targeting VEGFA may represent a viable therapeutic option in the context of cancer. This evidence concerns the gene BCL2 and cancer.